OR51I1 Inhibitors
OR51I1 inhibitors represent a specialized class of chemical compounds that target and modulate the activity of the OR51I1 receptor, a G-protein coupled receptor (GPCR) that is part of the extensive olfactory receptor (OR) family. These receptors are traditionally known for their role in the detection of odorants in the olfactory system, but emerging research has revealed their broader significance across various tissues, where they may play regulatory roles in cellular signaling pathways. The OR51I1 receptor itself is encoded by the OR51I1 gene, which belongs to a subset of olfactory receptors known for their expression outside the olfactory epithelium. These receptors can respond to specific endogenous and exogenous ligands, with OR51I1 exhibiting sensitivity to volatile and semi-volatile compounds that may modulate physiological responses at the cellular level. Inhibitors of OR51I1 are designed to prevent or dampen the receptor's activation by its natural ligands, thus potentially altering downstream signaling events mediated by the receptor's interaction with intracellular G-proteins.
From a molecular perspective, OR51I1 inhibitors are often characterized by their ability to specifically bind to the orthosteric or allosteric sites of the receptor, depending on their structural composition. These compounds may include small molecules, peptides, or even larger organic compounds, all capable of fitting into key binding domains of OR51I1. Through binding, they can block the receptor's conformational changes that would normally result in the initiation of intracellular signaling cascades involving second messengers like cyclic AMP (cAMP) or inositol phosphates. By inhibiting the receptor's function, these compounds offer valuable insight into the receptor's role in non-olfactory processes, such as cell proliferation, migration, and metabolic regulation. The study of OR51I1 inhibitors is expanding our understanding of the non-canonical roles that olfactory receptors may play in human biology, including intricate signaling mechanisms that extend beyond the traditional scope of sensory biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methimazole | 60-56-0 | sc-205747 sc-205747A | 10 g 25 g | $69.00 $110.00 | 4 | |
Methimazole suppresses thyroid hormone synthesis. Reduced thyroid hormone levels can downregulate the transcription of genes, including OR51I1, by altering the activity of thyroid hormone-responsive transcription factors. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic acid inhibits histone deacetylase, leading to hyperacetylation of histones. This hyperacetylation can decrease the transcriptional activity of several genes, potentially including the gene encoding OR51I1, by altering chromatin structure and accessibility. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol can extend the deacetylation of histones in promoter regions, potentially leading to a compact chromatin structure around the OR51I1 gene and a consequent decrease in its transcriptional initiation. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin binds to promoter regions of genes and can inhibit the activity of transcription factors. Binding within the OR51I1 gene promoter could downregulate its transcriptional activity and subsequent protein expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate′s inhibition of histone deacetylases can lead to an accumulation of acetylated histones, which may repress the transcription of certain genes, including potentially the OR51I1 gene, by altering gene accessibility. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid binds to retinoic acid receptors, which can repress gene transcription by recruiting co-repressor complexes to gene promoters. This may result in the decreased expression of target genes such as OR51I1. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea disrupts the ribonucleotide reductase enzyme, leading to a reduction in deoxyribonucleotide pools and inhibition of DNA synthesis, which could result in the suppression of OR51I1 gene expression during the S-phase of the cell cycle. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG can inhibit DNA methyltransferases, potentially leading to the hypomethylation of gene promoters. This hypomethylation within the OR51I1 promoter region may contribute to the reduction of its transcription. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein inhibits tyrosine kinases and can interfere with signal transduction pathways that control gene transcription. This interference might decrease the expression of genes like OR51I1 by reducing promoter activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid (Vorinostat), as an HDAC inhibitor, increases acetylation of histone proteins, which can lead to the compacting of chromatin structure and subsequent repression of gene transcription, possibly including the OR51I1 gene. | ||||||